Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Yescarta axicabtagene ciloleucel Relapsed or refractory follicular lymphoma Reimburse with clinical criteria and/or conditions Complete
Yervoy Ipilimumab Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Yervoy Ipilimumab First Line Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Yasmin Drospirenone /ethinyl estradiol Contraceptive, oral List Complete
Xyrem Sodium oxybate Narcolepsy Withdrawn
Xyrem Sodium oxybate Narcolepsy Do not list Complete
Xydalba dalbavancin Acute bacterial skin and skin structure infections Reimburse with clinical criteria and/or conditions Complete
Xultophy insulin degludec + liraglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide mHSPC Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide Non-metastatic castration-resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete